WaveMan
WaveMan · Company
TRDA · Entrada Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

TRDA Entrada Therapeutics (TRDA) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001689375
Quote by TradingView
Form 144 · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
81
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $26.1K priced

What the filings say about TRDA

Insiders, 180 days
-$10.9M net sold
1 buyer · 6 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$2.2M
1 notice

Entrada Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Entrada Therapeutics, Inc. insiders sold a net $10.9M of stock across 277 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
MPM BioVentures 2014, L.P.
SELL
2026-09-09 SEC
28,837
$205.6K
-31.3%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Sep 8, 2026.
  • The trade is 0.7% of the 3,885,115 shares held after it.
  • 2 other insiders sold within 30 days.
  • 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider MPM BioVentures 2014, L.P. sold about $205.6K of TRDA on Sep 9, 2026; 2 other insiders sold within 30 days and 81 funds added in the latest 13F quarter.
MPM BIOVENTURES 2018, L.P.
SELL
2026-09-09 SEC
28,837
$205.6K
-31.3%
Context
  • 12 earlier Form 4 trades (code P or S) here by this insider (1 buy, 11 sales), the last on Sep 8, 2026.
  • The trade is 0.7% of the 3,885,115 shares held after it.
  • 2 other insiders sold within 30 days.
  • 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider MPM BIOVENTURES 2018, L.P. sold about $205.6K of TRDA on Sep 9, 2026; 2 other insiders sold within 30 days and 81 funds added in the latest 13F quarter.
MPM BioVentures 2014, L.P.
SELL
2026-09-09 SECtraded 2026-09-08
192,500
$1.4M
-31.3%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Sep 4, 2026.
  • The trade is 4.9% of the 3,913,952 shares held after it.
  • 2 other insiders sold within 30 days.
  • 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider MPM BioVentures 2014, L.P. sold about $1.4M of TRDA on Sep 8, 2026; 2 other insiders sold within 30 days and 81 funds added in the latest 13F quarter.
MPM BIOVENTURES 2018, L.P.
SELL
2026-09-09 SECtraded 2026-09-08
192,500
$1.4M
-31.3%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (1 buy, 10 sales), the last on Sep 4, 2026.
  • The trade is 4.9% of the 3,913,952 shares held after it.
  • 2 other insiders sold within 30 days.
  • 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider MPM BIOVENTURES 2018, L.P. sold about $1.4M of TRDA on Sep 8, 2026; 2 other insiders sold within 30 days and 81 funds added in the latest 13F quarter.
MPM BioVentures 2014, L.P.
SELL
2026-09-09 SECtraded 2026-09-04
38,500
$273.7K
-31.3%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Sep 3, 2026.
  • The trade is 0.9% of the 4,106,452 shares held after it.
  • 3 other insiders sold within 30 days.
  • 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider MPM BioVentures 2014, L.P. sold about $273.7K of TRDA on Sep 4, 2026; 3 other insiders sold within 30 days and 81 funds added in the latest 13F quarter.
277 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 272 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$10.9M over 180 days
-$10.3M over 90 days · -$9.2M of it by a 10%+ holder
below 84% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
81 funds bought in last quarter
more than 60% of Pharma & Biotech
Revenue
-87.9% year over year
below 89% of Pharma & Biotech
Margin
-565.5% net margin
below 79% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
13.2% of the float short (float per yahoo 2026-10-26) · 9.9 days to cover · settled 2026-09-30
more than 63% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch TRDA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-31.1%12M
-32%+29%+90%+150%2025-102025-122026-022026-042026-062026-082026-10 2025-11-14 · PARMAR KUSH sold $1.8M2025-11-14 · 5AM Ventures V, L.P. sold $1.8M2026-09-08 · MPM BioVentures 2014, L.P. sold $1.4M2026-09-08 · MPM BIOVENTURES 2018, L.P. sold $1.4M2026-07-30 · PARMAR KUSH sold $795.3K2026-07-30 · 5AM Ventures V, L.P. sold $795.3K2026-08-10 · PARMAR KUSH sold $647.1K2025-11-12 · Baker Bros. Advisors (GP) LLC bought $625.2K2026-05-04 · Sethuraman Natarajan sold $398.7K2026-08-07 · 5AM Ventures V, L.P. sold $358.4K2026-08-07 · PARMAR KUSH sold $358.4K2026-08-31 · MPM BioVentures 2014, L.P. sold $309.4K2026-08-31 · MPM BIOVENTURES 2018, L.P. sold $309.4K2026-08-27 · MPM BioVentures 2014, L.P. sold $280.2K2026-08-27 · MPM BIOVENTURES 2018, L.P. sold $280.2K2026-09-04 · MPM BioVentures 2014, L.P. sold $273.7K2026-09-04 · MPM BIOVENTURES 2018, L.P. sold $273.7K2025-11-11 · Baker Bros. Advisors (GP) LLC bought $232.8K2026-09-03 · MPM BioVentures 2014, L.P. sold $231.3K2026-09-03 · MPM BIOVENTURES 2018, L.P. sold $231.3K2026-05-04 · Dowden Nathan J sold $229.9K2026-09-09 · MPM BioVentures 2014, L.P. sold $205.6K2026-09-09 · MPM BIOVENTURES 2018, L.P. sold $205.6K2026-09-01 · MPM BioVentures 2014, L.P. sold $205.4K2026-09-01 · MPM BIOVENTURES 2018, L.P. sold $205.4K2026-08-25 · MPM BIOVENTURES 2018, L.P. sold $200.0K2026-08-25 · MPM BioVentures 2014, L.P. sold $200.0K2025-11-10 · Baker Bros. Advisors (GP) LLC bought $182.9K2026-09-02 · MPM BioVentures 2014, L.P. sold $180.7K2026-09-02 · MPM BIOVENTURES 2018, L.P. sold $180.7K2026-08-24 · MPM BIOVENTURES 2018, L.P. sold $158.7K2026-08-24 · MPM BioVentures 2014, L.P. sold $158.7K2026-03-10 · Dowden Nathan J sold $155.2K2026-03-10 · WENTWORTH KORY JAMES sold $148.3K2025-11-20 · BAKER FELIX bought $121.4K2025-11-20 · BAKER FELIX bought $118.7K2026-08-26 · MPM BIOVENTURES 2018, L.P. sold $102.9K2026-08-26 · MPM BioVentures 2014, L.P. sold $102.9K2026-03-04 · WENTWORTH KORY JAMES sold $97.9K2025-11-12 · Baker Bros. Advisors (GP) LLC bought $91.4K2025-11-21 · WENTWORTH KORY JAMES sold $88.9K2025-11-11 · Baker Bros. Advisors (GP) LLC bought $86.5K2026-07-30 · 5AM Ventures V, L.P. filed to sell $2.2M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns TRDA: institutional holders (13F)

13F holdings, latest reported quarter
BAKER BROS. ADVISORS LP
5,072,730 sh
$37.3M
5AM Venture Management, LLC
4,056,379 sh
$29.9M
BlackRock, Inc.
2,583,333 sh
$19.0M
Merck & Co., Inc.
1,739,768 sh
$12.8M
VANGUARD CAPITAL MANAGEMENT LLC
1,269,634 sh
$9.3M

Congress trades in TRDA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

TRDA planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
5AM Ventures V, L.P.
Filed 2026-07-30
$2.2M

TRDA mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Allspring Disciplined Small Cap Fund
$460.9K position · as of 2026-06-30
0.3%
Royce Small-Cap Value Fund
$231.3K position · as of 2026-06-30
0.2%
Royce Capital Fund - Small-Cap Portfolio
$378.8K position · as of 2026-06-30
0.2%
NVIT Small Cap Value Fund
$320.6K position · as of 2026-06-30
0.1%
Harbor Human Capital Factor US Small Cap ETF
$226.6K position · as of 2026-07-31
0.1%
Ultra-Small Company Market Fund
$184.0K position · as of 2026-06-30
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
3 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 2
1 active
2
Multi-phase
2 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $10.9M sold by insiders over 180 days, 81 funds added last quarter, $2.2M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

TRDA financials

Revenue growth
-87.9%
XBRL, annual
Net margin
-565.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$4.7M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-3,538%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$134.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-54.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-44.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-50.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-78.2%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$25.4M$210.8M$129.0Mn/a
Operating income-$157.9M$47.0M-$3.2M-$97.2M
Net income-$143.8M$65.6M-$6.7M-$94.6M
EPS (diluted)-3.471.68-0.20-3.02
Operating cash flow-$128.5M-$41.6M$139.8M-$93.8M
Cash$90.4M$101.2M$67.6M$45.2M
SEC XBRL, fiscal years, as known on 2026-10-28

TRDA Stock Sonar score 5/7 axes

Find similar shapesCompare

TRDA ranks highest on institutional and government (60th percentile) and profitability (50th), and lowest on growth (11th), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
50
Inputs
  • Return on equity-54.1% · 51 pct, sector of 545
  • Return on assets-44.3% · 48 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-50.0% · 50 pct, sector of 576
Growth
11
Inputs
  • Revenue growth, YoY-87.9% · 11 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
35
Inputs
  • Net Form 4 buying (codes P and S), 180d-$10.9M · 14 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
60
Inputs
  • Funds adding, latest quarter81 · 60 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
44
Inputs
  • Short interest, % of float+13.2% · 29 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+9.2% · 58 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

TRDA filings, in plain words

Are Entrada Therapeutics insiders buying or selling TRDA?

In the 180 days to 2026-10-28, Entrada Therapeutics insiders were net sellers, a net $10.9M: $29.3K of purchases and $11.0M of sales reported on Form 4, by 1 buyer and 6 sellers.

Are there planned insider sales of TRDA?

Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $2.2M of stock; the latest, by 5AM Ventures V, L.P., was filed 2026-07-30.

Read the full summary

In the 180 days to 2026-10-28, Entrada Therapeutics insiders were net sellers of TRDA, a net $10.9M across purchases and sales reported on Form 4 by 1 buyer and 6 sellers. Most of that figure, $9.2M, came from a holder of 10% or more rather than an officer or director. Sales outweighed purchases more than tenfold by value. None of the 35 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $2.2M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies